LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

Bristol Myers Squibb And The New Wave Of Cancer Drugs
Peter Geschek • BMY, RHHBY.OB, MRK • Mon, May 20, 16:34 ET
Johnson & Johnson's Short-Term Pipeline
Jean-Christophe Larsimont • JNJ • Mon, May 20, 15:15 ET
AstraZeneca: A Dividend Payer With An Attractive Growth Prospect
Fund Gurus • AZN • Mon, May 20, 09:59 ET
Johnson & Johnson Dividend Stock Analysis
Dividends4Life • JNJ • Mon, May 20, 03:54 ET
Johnson & Johnson: At The Crossroads - Part III
Robert Honeywill • BSX, SSH, JNJ • Thu, May 16, 05:47 ET
Busy Day For Bristol-Myers Options As Shares Sprint Higher
Interactive Brokers • TIBX, WM, BMY • Wed, May 15, 14:10 ET
Can Merck's Pipeline Offset The Pain From Major Patent Expirations?
Trefis • MRK • Tue, May 14, 18:04 ET
Pfizer's Direct-To-Consumer Campaigns: A Model For The Future?
Peter Geschek • PFE • Mon, May 13, 15:03 ET
Baby Boomers Are Money-Making Machines For Big Pharma
Tedra DeSue • JNJ, PFE, MRK • Mon, May 13, 11:41 ET
Buffett Style Valuation Of Johnson & Johnson
AquaResearch • JNJ • Mon, May 13, 09:56 ET
Johnson & Johnson: An Investment In A Healthcare Conglomerate That Cannot Go Wrong
Emerging Equities • JNJ • Mon, May 13, 09:46 ET
The Game Of Risk
Inzkeeper • JNJ • Mon, May 13, 06:27 ET
Is Johnson & Johnson Heading Off The Patent Cliff?
Being Unordinary • NVS, PFE, JNJ • Mon, May 13, 06:17 ET
Shire's New Rare Disease Deal: Interesting Science Meets Unique Financing
Alan Kotok • SHPG • Mon, May 13, 05:47 ET
Johnson & Johnson: Why I'm Cautious
Sammy Pollack • JNJ • Mon, May 13, 04:23 ET
Johnson & Johnson: At The Crossroads - Part II
Robert Honeywill • BSX, SSH, STJ • Fri, May 10, 18:46 ET
Merck's Liptruzet: A Cause For Shame?
Derek Lowe • MRK • Thu, May 9, 11:46 ET
Johnson & Johnson: Banking On Industry Revival
Fundamental Analyst • JNJ • Thu, May 9, 07:36 ET
Keryx: A Small Biotech With Many Catalysts
George Rho • KERX • Wed, May 8, 09:30 ET
Whisper Number Impact: Earnings Preview For Keryx Biopharmaceuticals
WhisperNumber • KERX • Tue, May 7, 15:39 ET
Eating Up Dividends With Abbott Laboratories
Abba's Aces • ABT • Tue, May 7, 13:09 ET
An Update On Pfizer's Recently Approved Drugs
Jon Crowley • MRK, PFE • Tue, May 7, 11:25 ET
Merck: A Negative Growth Story
Jeffrey To • MRK • Tue, May 7, 10:19 ET
Rating Agencies Turn Negative On Merck
Tedra DeSue • MRK • Tue, May 7, 04:52 ET
Merck Pharmaceuticals' Suvorexant: A Wake-Up Call
Healthcare Specialist • SNY, MRK • Mon, May 6, 20:01 ET
A New Normal For Johnson & Johnson's Dividend
Tim McAleenan Jr. • JNJ • Mon, May 6, 01:30 ET
Bristol-Myers Has The Future Of Oncology Therapies
Bio Matt • BMY • Sun, May 5, 05:12 ET
Johnson & Johnson: At The Crossroads
Robert Honeywill • JNJ • Fri, May 3, 09:12 ET
A.P. Pharma: Management Change Is A Positive For The Stock
Smith On Stocks • APPA.OB • Fri, May 3, 08:18 ET
Zogenix Poised For 40% Haircut As Zohydro Decision Approaches
PropThink • ZGNX • Thu, May 2, 12:37 ET
Mapping Merck: Q1 And Beyond
Vlad Deshkovich • MRK • Thu, May 2, 12:02 ET
Johnson & Johnson: Blue Chip Chaser Vs. The Value Hunter
Tradevestor • JNJ • Thu, May 2, 01:06 ET
Whisper Number Impact: Earnings Preview For Merck
WhisperNumber • MRK • Tue, Apr 30, 21:57 ET
3 Pharmaceutical Companies Awaiting FDA Approval, Part II
Emerging Equities • GSK, MRK, RPTP • Tue, Apr 30, 16:47 ET
Pssstt! Pfizer Is Not Executing And Is Overvalued
Deep Dives • PFE • Tue, Apr 30, 16:32 ET
Diabetes Risk Sharing Moves Up A Gear
EP Vantage • MRK, PFE • Tue, Apr 30, 13:23 ET
New Product Approvals Likely To Spur Growth For Johnson & Johnson
Emerging Equities • JNJ • Tue, Apr 30, 12:04 ET
Zohydro - Is There Enough Upside For Zogenix?
Bay Area Biotech • ZGNX • Tue, Apr 30, 12:02 ET
Whisper Number Impact: Earnings Preview For Pfizer
WhisperNumber • PFE • Mon, Apr 29, 15:56 ET
Johnson & Johnson: Should You Chase The Price Uptrend?
Stock Gamer • JNJ • Mon, Apr 29, 06:20 ET
Abbott Is A Solid Long-Term Investment
IAEResearch • ABBV, ABT • Sun, Apr 28, 05:51 ET
Bristol-Myers Squibb's New Drugs Can Help Reverse Its Sinking Revenue
Trefis • BMY • Fri, Apr 26, 18:10 ET
Enbrel's Asian Biosimilar Competitors
Peter Geschek • PFE, AMGN, CPLFY.OB • Fri, Apr 26, 09:44 ET
Eli Lilly's Promising Stage III Pipeline Could Jumpstart Its Dividend
Valuentum • LLY • Fri, Apr 26, 00:19 ET
The 3 Drivers Behind The Big Pharma Rally
BubbleBustInvesting • LLY, MRK, PFE • Thu, Apr 25, 17:49 ET
J&J's Cash Flow Spells Dividend Safety And Growth
Valuentum • JNJ • Thu, Apr 25, 04:33 ET
Whisper Number Impact: Earnings Preview For Bristol-Myers Squibb
WhisperNumber • BMY • Wed, Apr 24, 16:40 ET
Bristol-Myers Squibb Preview: Performance Of New Drugs Is Key
Trefis • BMY • Wed, Apr 24, 15:50 ET
Will The Big Pharmaceuticals Fall Off A Patent Cliff?
Fund Gurus • AZN, GSK, LLY • Wed, Apr 24, 15:15 ET
Merck: Here Is What You Should Do At The 52-Week High
Stock Gamer • MRK • Wed, Apr 24, 09:03 ET

First Page
Previous Page
1 - 50 of 2627
Next Page
Last Page